Table 5.
Summary of HLA genotype-clinical phenotype correlations in NMOSD.
| HLA allele | Confer susceptibility or resistance | Clinical and laboratory findings | Effects on clinical phenotype |
|---|---|---|---|
| DRB1*08:02 | Susceptibility | OCBs | Decreased |
| AID/autoantibodies | Increased | ||
| Autoantibodies | Increased | ||
| Anti-SS-A/SS-B Ab | Increased | ||
| DPB1*05:01 | Susceptibility | PI | Decreased (due to long disease duration?) |
| AID | Increased | ||
| Sjögren syndrome | Increased | ||
| Anti-SS-A/SS-B Ab | Increased | ||
| DRB1*09:01 | Resistance | AID | Increased |
| Sjögren syndrome | Increased |
If the effects were derived from only 5 or less than 5 positive cases, such findings were regarded as too preliminary, and therefore they are not described in the table.
Ab antibody, AID autoimmune disease, ANA anti-nuclear antibody, NMOSD neuromyelitis optica spectrum disorders, OCBs oligoclonal IgG bands, PI Progression Index.